The 'King of Biotech' reaches SEC settlement pact; Sanofi gets positive new data on Fluzone;

@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech

@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. | Follow @JohnCFierce

@EmilyMFierce: High copper levels implicated in Alzheimer's disease. Story | Follow @EmilyMFierce

> David Blech, once known in some circles as the "King of Biotech," has reached a settlement deal with the SEC regarding charges of market manipulation of shares of Pluristem Therapeutics ($PSTI) and Intellect Neurosciences. Story

> Sanofi ($SNY) is touting new data on patients 65 and older for its high-dose version of Fluzone. Story

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev

@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce

@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce

@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce

> Medtronic fails to stop patient's Infuse lawsuit. News

> Investment bank launches healthcare-focused crowdfunding option. Item

Pharma News

@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma

@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce

@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story Follow @CarlyHFierce

> Australia to track Yervoy patients to see if it's worth the $110K price. News

> Sanofi eyes superiority claim for Fluzone High-Dose after trial boost. More

CRO News

> U.K. outfit bets on early-phase outsourcing. News

> CRO Psi jumps into India. More

> Vince & Associates eyes gastro trials with expansion. Article

> Study: CROs dishing out bonuses to halt high turnover. Story

> Icon dives into adaptive trial monitoring. News

Biotech IT News

> Capgemini taps Amazon cloud for Big Data analytics. Story

> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article

> Google bolsters security of cloud data storage service. More

> FDA pilot project ups benefits of IT supply chain investments. News

> EMA to start accepting digital signatures next month. Story

And Finally… Investigators at Johns Hopkins say they have identified a new target for drug developers focused on Parkinson's disease. "Not only were we able to identify the mechanism that could cause progressive cell death in both inherited and non-inherited forms of Parkinson's, we found there were already compounds in existence that can cross into the brain and block this from happening," says Johns Hopkins' Valina Dawson. Release

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.